First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen–Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer

Kjetil Berner; Eivor Hernes; Monika Kvassheim; Mona-Elisabeth Revheim; Julie Bastiansen; Silje Selboe; Charlotte L. Bakken; Simen R. Grønningsæter; Øyvind S. Bruland; Roy H. Larsen; Lily Bouzelmat; Vicki L. Jardine; Caroline Stokke

doi:10.2967/jnumed.124.269299

Research ArticleClinical Investigations

Open Access

First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen–Targeted ²¹²Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer

Kjetil Berner, Eivor Hernes, Monika Kvassheim, Mona-Elisabeth Revheim, Julie Bastiansen, Silje Selboe, Charlotte L. Bakken, Simen R. Grønningsæter, Øyvind S. Bruland, Roy H. Larsen, Lily Bouzelmat, Vicki L. Jardine and Caroline Stokke

Journal of Nuclear Medicine March 2025, jnumed.124.269299; DOI: https://doi.org/10.2967/jnumed.124.269299

Kjetil Berner

1Department of Oncology, Oslo University Hospital, Oslo, Norway;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Eivor Hernes

2Department of Nuclear Medicine, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Monika Kvassheim

3Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway;

4Institute of Clinical Medicine, University of Oslo, Oslo, Norway;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mona-Elisabeth Revheim

2Department of Nuclear Medicine, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway;

4Institute of Clinical Medicine, University of Oslo, Oslo, Norway;

5Intervention Centre, Oslo University Hospital, Oslo, Norway;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Julie Bastiansen

1Department of Oncology, Oslo University Hospital, Oslo, Norway;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Silje Selboe

2Department of Nuclear Medicine, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Charlotte L. Bakken

1Department of Oncology, Oslo University Hospital, Oslo, Norway;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Simen R. Grønningsæter

3Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway;

6Department of Physics, University of Oslo, Oslo, Norway;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Øyvind S. Bruland

1Department of Oncology, Oslo University Hospital, Oslo, Norway;

4Institute of Clinical Medicine, University of Oslo, Oslo, Norway;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Roy H. Larsen

7Sciencons AS, Oslo, Norway; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lily Bouzelmat

8ARTBIO Limited, London, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Vicki L. Jardine

8ARTBIO Limited, London, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Caroline Stokke

3Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway;

6Department of Physics, University of Oslo, Oslo, Norway;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 66, Issue 5

May 1, 2025

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen–Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen–Targeted ²¹²Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer

Journal of Nuclear Medicine Mar 2025, jnumed.124.269299; DOI: 10.2967/jnumed.124.269299

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen–Targeted ²¹²Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer

Journal of Nuclear Medicine Mar 2025, jnumed.124.269299; DOI: 10.2967/jnumed.124.269299

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Keywords

mCRPC
PSMA
212Pb
imaging
α-radioligand therapy
targeted α-therapy

Main menu

User menu

Search

First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen–Targeted ²¹²Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords